BioCentury
ARTICLE | Strategy

Genzyme Corp.

August 1, 1994 7:00 AM UTC

GENZ acquired BSRF in a tax-free stock swap and created a new business unit within GENZ, Genzyme Tissue Repair, whose equity ownership will be publicly traded stock initially held almost entirely by GENZ and BSRF shareholders.

GENZ is contributing five tissue repair products to the new unit, three of which are in clinical trials. Vianain enzyme removes nonviable tissue. It is in Phase II trials for burns and will begin Phase I/II skin ulcer trials this fall. Tissue plasminogen activator (tPA) is being studied under a physician's IND for removal of nonviable tissue in skin ulcers. ...